Heart / Stroke-RelatedHigh Cholesterol Heart / Stroke-RelatedCardiologyFamily PracticeInternal MedicinePathologyPharmacyCardiovascular DiseasesHigh Cholesterol
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Jan. 19, 2018 (HealthDay News) -- For patients with autosomal recessive hypercholesterolemia (ARH), low-density lipoprotein cholesterol (LDL-C) levels remain high despite intensive treatment, according to a study published in the Jan. 23 issue of the Journal of the American College of Cardiology.
Laura D'Erasmo, M.D., Ph.D., from the Sapienza University of Rome, and colleagues obtained data for 52 patients with ARH and assessed changes in lipid management, achievement of LDL-C goals, and cardiovascular outcomes.
The researchers observed an increase in the use of high-intensity statin and ezetimibe in combination with lipoprotein apheresis during a mean follow-up of 14.1±7.3 years; lomatipide was added in six patients. At nadir, the mean LDL-C was 164±85.1 mg/dL (−69.6 percent from baseline); a better response was seen in patients taking lomitapide (−88.3 percent). LDL-C of <100 mg/dL was reached by 23.1 percent of patients. Incident atherosclerotic cardiovascular disease (ASCVD) occurred in 26.9 percent of patients during follow-up, and 11.5 percent had a new diagnosis of aortic valve stenosis. There were no cases of incident stroke. Major predictors of incident ASCVD included age (≥30 years) and presence of coronary artery disease at diagnosis.
"Despite intensive treatment, LDL-C in ARH patients remains far from targets, and this translates into a poor long-term cardiovascular prognosis," the authors write. "Our data highlight the importance of an early diagnosis and treatment and confirm the fact that an effective treatment protocol for ARH is still lacking."
Several authors disclosed financial ties to pharmaceutical companies, including Aegerion, which partly funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 28, 2022
Read this Next
Other Trending Articles